BR112017020081A2 - análogos deuterados de etifoxina, seus derivados e usos dos mesmos - Google Patents

análogos deuterados de etifoxina, seus derivados e usos dos mesmos

Info

Publication number
BR112017020081A2
BR112017020081A2 BR112017020081A BR112017020081A BR112017020081A2 BR 112017020081 A2 BR112017020081 A2 BR 112017020081A2 BR 112017020081 A BR112017020081 A BR 112017020081A BR 112017020081 A BR112017020081 A BR 112017020081A BR 112017020081 A2 BR112017020081 A2 BR 112017020081A2
Authority
BR
Brazil
Prior art keywords
etifoxin
derivatives
deuterated
deuterated analogues
analogs
Prior art date
Application number
BR112017020081A
Other languages
English (en)
Other versions
BR112017020081B1 (pt
Inventor
Dasse Olivier
Original Assignee
Anvyl Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anvyl Llc filed Critical Anvyl Llc
Publication of BR112017020081A2 publication Critical patent/BR112017020081A2/pt
Publication of BR112017020081B1 publication Critical patent/BR112017020081B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

esta invenção se refere a análogos deuterados de etifoxina de fórmula 1, solvatos, pró-fármacos e sais farmaceuticamente aceitáveis dos mesmos, bem como a métodos para sua preparação e uso, e a composições farmacêuticas. resumidamente, esta invenção é geralmente dirigida a análogos deuterados de etifoxina, bem como a métodos para sua preparação e uso, e a composições farmacêuticas contendo o mesmo.
BR112017020081-3A 2015-03-20 2016-03-18 Composto análogo deuterado de etifoxina, composição farmacêutica que o compreende e usos do referido composto BR112017020081B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135979P 2015-03-20 2015-03-20
US62/135,979 2015-03-20
PCT/US2016/023231 WO2016154039A1 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Publications (2)

Publication Number Publication Date
BR112017020081A2 true BR112017020081A2 (pt) 2018-06-05
BR112017020081B1 BR112017020081B1 (pt) 2021-11-30

Family

ID=56977741

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020081-3A BR112017020081B1 (pt) 2015-03-20 2016-03-18 Composto análogo deuterado de etifoxina, composição farmacêutica que o compreende e usos do referido composto

Country Status (20)

Country Link
US (4) US10080755B2 (pt)
EP (1) EP3347006B1 (pt)
JP (3) JP6762507B2 (pt)
KR (1) KR102290766B1 (pt)
CN (1) CN107530323B (pt)
AU (2) AU2016235495B2 (pt)
BR (1) BR112017020081B1 (pt)
CA (1) CA2979853C (pt)
DK (1) DK3347006T3 (pt)
ES (1) ES2928396T3 (pt)
HR (1) HRP20221240T1 (pt)
HU (1) HUE060240T2 (pt)
IL (2) IL270627B2 (pt)
LT (1) LT3347006T (pt)
MX (1) MX2017011978A (pt)
PL (1) PL3347006T3 (pt)
PT (1) PT3347006T (pt)
RS (1) RS63654B1 (pt)
SI (1) SI3347006T1 (pt)
WO (1) WO2016154039A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3347006T (lt) * 2015-03-20 2022-10-25 Gaba Therapeutics Inc. Deuterinti etifoksino analogai, jų dariniai ir panaudojimai
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
JP2021519276A (ja) * 2018-03-23 2021-08-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用
AU2019270173A1 (en) * 2018-05-18 2020-12-03 Ovid Therapeutics Inc. Methods of treating attention deficit hyperactivity disorder
CN112125862A (zh) * 2019-06-25 2020-12-25 上海安谱实验科技股份有限公司 一种稳定同位素标记的阿特拉津-d5及其合成方法
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
WO2023218251A1 (en) * 2022-05-10 2023-11-16 Clearsynth Labs Limied Novel deuterium-enriched nefazodone analogues and method for preparing thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
FR2888748B1 (fr) 2005-07-19 2007-10-12 Biocodex Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
US20080039453A1 (en) * 2006-03-20 2008-02-14 David Putman Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use
US8110569B2 (en) * 2006-03-20 2012-02-07 The Regents Of The University Of California Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
KR20130092558A (ko) * 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
US20140121407A1 (en) 2011-07-05 2014-05-01 Research Foundation Itsuu Laboratory Deuterated phenylpropionic acid derivative
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
LT3347006T (lt) * 2015-03-20 2022-10-25 Gaba Therapeutics Inc. Deuterinti etifoksino analogai, jų dariniai ir panaudojimai

Also Published As

Publication number Publication date
HRP20221240T1 (hr) 2022-12-09
IL270627A (pt) 2019-12-31
KR20170137085A (ko) 2017-12-12
IL270627B2 (en) 2023-03-01
US20190015419A1 (en) 2019-01-17
JP7376668B2 (ja) 2023-11-08
CA2979853A1 (en) 2016-09-29
DK3347006T3 (da) 2022-10-17
IL254567B (en) 2020-03-31
AU2016235495B2 (en) 2020-05-14
BR112017020081B1 (pt) 2021-11-30
JP6762507B2 (ja) 2020-09-30
US10080755B2 (en) 2018-09-25
ES2928396T3 (es) 2022-11-17
EP3347006B1 (en) 2022-07-27
US20200405726A1 (en) 2020-12-31
AU2016235495A1 (en) 2017-10-05
CN107530323B (zh) 2021-05-04
CN107530323A (zh) 2018-01-02
IL254567A0 (en) 2017-11-30
US20230263805A1 (en) 2023-08-24
WO2016154039A1 (en) 2016-09-29
LT3347006T (lt) 2022-10-25
AU2020201728B2 (en) 2021-12-23
US20180064717A1 (en) 2018-03-08
KR102290766B1 (ko) 2021-08-19
US10736901B2 (en) 2020-08-11
CA2979853C (en) 2021-05-11
EP3347006A1 (en) 2018-07-18
PL3347006T3 (pl) 2022-11-14
AU2020201728A1 (en) 2020-03-26
PT3347006T (pt) 2022-10-17
IL270627B (en) 2022-11-01
RS63654B1 (sr) 2022-11-30
HUE060240T2 (hu) 2023-02-28
US11672805B2 (en) 2023-06-13
JP2021001174A (ja) 2021-01-07
EP3347006A4 (en) 2019-04-24
JP2018508592A (ja) 2018-03-29
SI3347006T1 (sl) 2022-11-30
JP2023009114A (ja) 2023-01-19
MX2017011978A (es) 2018-02-09

Similar Documents

Publication Publication Date Title
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112016016844A2 (pt) Compostos heterocíclicos
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CR20160527A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY35536A (es) ?derivados de sulfonamida?.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: ANVYL, LLC (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO 870200117150 DE 15/09/2020, E NECESSARIO QUE AMBOS DOCUMENTOS DE CESSAO POSSUAM LEGALIZACAO CONSULAR OU APOSTILA, SEGUNDO CONVENCAO DE HAIA.

B25A Requested transfer of rights approved

Owner name: GABA THERAPEUTICS, LLC (US)

B25A Requested transfer of rights approved

Owner name: GABA THERAPEUTICS, INC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2016, OBSERVADAS AS CONDICOES LEGAIS.